Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20288415 | 0.94 | MAPT (0.41) | KDM1AMAPK1RAB9AGNAI3GNAO1 | |
| SCHEMBL3982710 | 0.86 | ALDH1A1 (0.42) | KDM1AMAPK1RAB9AALDH1A1PKM | |
| SCHEMBL311930 | 0.84 | PAOX (0.42) | KDM1ARAB9AALDH1A1PKMMAPT | |
| SCHEMBL23191089 | 0.79 | — | — | |
| SCHEMBL15485592 | 0.79 | HRH3 (0.52) | MAPK1MAPT | |
| SCHEMBL4422272 | 0.78 | PAOX (0.46) | GNAI3GNAO1GNAI1ALDH1A1PKM | |
| SCHEMBL3957874 | 0.78 | ALDH1A1 (0.37) | KDM1AMAPK1RAB9AGNAI3GNAO1 | |
| SCHEMBL6659406 | 0.78 | KDM1A (0.48) | KDM1AMAPK1RAB9AGNAI3GNAO1 | |
| SCHEMBL6663102 | 0.78 | GNAI3 (0.50) | KDM1AMAPK1RAB9AGNAI3GNAO1 | |
| SCHEMBL18396589 | 0.78 | ALDH1A1 (0.31) | ALDH1A1PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922547-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9428512-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150299204-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC | 2015-10-22 | — | — | US | disclosed |
| EP-2922547-A1 | NOVEL COMPOUNDS | Glaxosmithkline LLC (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081643-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-05-30 | — | — | WO | disclosed |
| US-8093229-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1869027-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2006-10-05 | — | — | US | disclosed |
| WO-2006105372-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | KDM1A 4107/4885MAPK1 1631/4885RAB9A 2878/4885 |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | KDM1A 3978/4885MAPK1 1174/4885RAB9A 2795/4885 |
| US-20150299204-A1 | NOVEL COMPOUNDS | IFNG, IRF3, IFNAR1 | KDM1A 3048/4885MAPK1 1287/4885RAB9A 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.